Dar-Odeh Najla, Elsayed Shadia, Babkair Hamzah, Abu-Hammad Shaden, Althagafi Nebras, Bahabri Rayan, Eldeen Yasmin Salah, Aljohani Wejdan, Abu-Hammad Osama
College of Dentistry, Taibah University, Al Madinah, Al Munawara, Saudi Arabia.
School of Dentistry, University of Jordan, Amman, Jordan.
J Dent Sci. 2021 Jul;16(3):806-816. doi: 10.1016/j.jds.2020.11.007. Epub 2020 Nov 19.
BACKGROUND/PURPOSE: Several pharmacotherapeutic methods have been used for the treatment of COVID-19 with varying degrees of success. No definitive treatment or vaccine has been officially approved to-date. This review aimed to highlight COVID-19 pharmacotherapeutic agents that are relevant to dental practice in terms of their clinical indications in COVID-19 and dental practice, as well as their adverse effects as they impact the dental patient.
Systematic search was performed using the following keywords combinations: Pharmacotherapy AND COVID-19 OR Pharmacotherapy AND SARS-CoV-2 OR Treatment AND COVID-19. Studies were categorized according to the type of pharmacotherapy used. Pharmacotherapeutic agents were extracted and only those relevant to dental practice were included for review.
For analysis, a total of 79 clinical trials research articles were included that included COVID-19 pharmacotherapeutic agents relevant to dental practice. Those were analgesics (paracetamol; non-steroidal anti-inflammatory agents); antibiotics (azithromycin, doxycycline, metronidazole); antivirals (penciclovir); and immunomodulatory agents (hydroxychloroquine, corticosteroids). While some COVID-19 drugs are less relevant to dental practice, as antivirals and hydroxychloroquine, their association with long-term adverse effects requires adequate knowledge among dental practitioners.
Many of COVID-19 pharmacotherapeutic agents are used to treat oral diseases particularly orofacial pain and inflammatory conditions. Furthermore, some of these drugs may induce adverse effects that complicate dental treatment. Thorough knowledge of COVID-19 therapy and its dental implications is essential for dental practitioners, and is expected to contribute to a better understanding and effective utilization of these therapeutic agents.
背景/目的：多种药物治疗方法已用于治疗新型冠状病毒肺炎（COVID-19），取得了不同程度的成功。迄今为止，尚无明确的治疗方法或疫苗获得官方批准。本综述旨在强调与牙科实践相关的COVID-19药物治疗药物，包括它们在COVID-19和牙科实践中的临床适应症，以及对牙科患者产生影响时的不良反应。
使用以下关键词组合进行系统检索：药物治疗与COVID-19、药物治疗与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、治疗与COVID-19。根据所使用的药物治疗类型对研究进行分类。提取药物治疗药物，仅纳入与牙科实践相关的药物进行综述。
为进行分析，共纳入79篇临床试验研究文章，其中包括与牙科实践相关的COVID-19药物治疗药物。这些药物包括镇痛药（对乙酰氨基酚；非甾体抗炎药）、抗生素（阿奇霉素、多西环素、甲硝唑）、抗病毒药（喷昔洛韦）和免疫调节剂（羟氯喹、皮质类固醇）。虽然一些COVID-19药物与牙科实践的相关性较低，如抗病毒药和羟氯喹，但它们与长期不良反应的关联要求牙科从业者有足够的了解。
许多COVID-19药物治疗药物用于治疗口腔疾病，尤其是口腔面部疼痛和炎症性疾病。此外，其中一些药物可能会引起不良反应，使牙科治疗复杂化。牙科从业者全面了解COVID-19治疗及其对牙科的影响至关重要，有望有助于更好地理解和有效利用这些治疗药物。
